Kiniksa Pharmaceuticals

Yahoo Finance • 27 days ago

7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?

(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impul... Full story

Yahoo Finance • last month

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

LONDON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferences in September: Citi 2025 Biophar... Full story

Yahoo Finance • 2 months ago

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Exhibits High Growth Momentum and Technical Breakout Potential

Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA [https://www.chartmill.com/stock/quote/KNSA]) has become a notable candidate for investors using a high growth momentum strategy combined with technical breakout analysis. This approac... Full story

Yahoo Finance • 2 months ago

KINIKSA PHARMACEUTICALS INTE (NASDAQ:KNSA): A Strong Growth Stock with a Positive Technical Breakout

Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA [https://www.chartmill.com/stock/quote/KNSA]) has appeared as a notable candidate through a screening method that mixes technical and fundamental analysis, specifically looking for sol... Full story

Yahoo Finance • 2 months ago

High Growth Tech Stocks To Watch In The US August 2025

As the U.S. market experiences a mix of record highs and tempered expectations due to recent inflation reports, investors are closely monitoring economic indicators that could influence Federal Reserve policy decisions on interest rates. I... Full story

Yahoo Finance • 2 months ago

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) – An Affordable Growth Stock with Strong Fundamentals and Fair Valuation

Growth investing often focuses on companies with strong revenue and earnings increases, but prices can rise quickly in popular stocks. The "Affordable Growth" strategy balances these factors by finding stocks with good growth potential tha... Full story

Yahoo Finance • 2 months ago

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Aligns with Minervini’s Trend Model as a Strong Momentum Pick

KINIKSA PHARMACEUTICALS: A STRONG MOMENTUM PICK ALIGNING WITH MINERVINI’S TREND MODEL Mark Minervini’s trend-based strategy aims to find stocks with strong upward movement, backed by both technical and fundamental factors. His method uses... Full story

Yahoo Finance • 2 months ago

Kiniksa Pharmaceuticals stock hits 52-week high at 30.8 USD

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) stock reached a 52-week high, touching 30.8 USD, marking a significant milestone for the company. The stock has shown impressive momentum with a 30.88% gain over the past six months, supported by... Full story

Yahoo Finance • 2 months ago

Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $625 - $640 million – – KPL-387 Phase 2/3 clinical trial in recurren... Full story

Yahoo Finance • 2 months ago

Kiniksa Pharmaceuticals International, plc Q2 2025 Earnings Preview

* Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA [https://seekingalpha.com/symbol/KNSA]) is scheduled to announce Q2 earnings results on Tuesday, July 29th, before market open. The consensus EPS Estimate is $0.22 [https://seeki... Full story

Yahoo Finance • 3 months ago

Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

LONDON, July 24, 2025 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its s... Full story

Yahoo Finance • 3 months ago

The Implied Analyst 12-Month Target For VBK

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 4 months ago

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – KPL-387 Phase 1 single ascending dose data support profile for monthly dosing – – Presentation and webcast at Jefferies 2025 Global Healthcare... Full story

Yahoo Finance • 4 months ago

Small-caps showing signs of potential breakout – BTIG

[Small Cap write on sticky notes isolated on Office Desk. Stock market concept] syahrir maulana The Russell 2000 Index (NYSEARCA:IWM [https://seekingalpha.com/symbol/IWM]) is attempting to break out of a seven-month downtrend, potentially... Full story

Yahoo Finance • 8 months ago

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively – – ARCALYST 2025 net product revenue expected to be $560 - $580 million – – KPL-387 Phase 2/3 clinical trial in rec... Full story

Yahoo Finance • 8 months ago

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report it... Full story

Yahoo Finance • last year

Roth analysis: Has volatility created a trigger warning for stocks?

Investing.com - The financial markets have experienced a roller coaster ride of late, prompting analysts at Roth to issue a technical strategy update. Despite ending last week down just 0.04%, the S&P 500's minor dip feels like a victory... Full story

Yahoo Finance • 2 years ago

Investors in Kiniksa Pharmaceuticals (NASDAQ:KNSA) have seen returns of 30% over the past year

Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right individual stocks, you could make more than that. To wit, the Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) share price is... Full story

Yahoo Finance • 2 years ago

Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023

HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8:30 a.m. Eastern Time to report its t... Full story

Yahoo Finance • 2 years ago

12 Cheap Biotech Stocks Smart Investors Are Piling Into

In this piece, we will take a look at 12 cheap biotechnology stocks that smart investors are piling into. If you want to skip our introduction to the biotechnology industry and how it might be affected by recent economic and stock market t... Full story